HYPERMARKER
Research type
Research Study
Full title
Personalised pharmacometabolomic-guided strategy trial to optimise treatment for hypertension (HYPERMARKER)
IRAS ID
354889
Contact name
Dipak Kotecha
Contact email
Sponsor organisation
Research Governance and Integrity, University of Birmingham
ISRCTN Number
ISRCTN29385951
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 2 months, 5 days
Research summary
High blood pressure (hypertension) affects 1 in 3 adults and can lead to serious health issues like strokes and heart attacks. Medication can lower blood pressure (BP) and reduce complications. Choosing the right medication can be challenging, potentially leading to side effects or poor control.
HYPERMARKER is testing whether providing doctors with additional information when they make a blood pressure prescription choice can improve a patient’s overall blood pressure management. This includes relevant clinical information and personalised results from blood tests, brought together using computer programs (machine learning) – ‘smart approach’. The blood tests check for small substances naturally produced by the body called metabolites.
Developed with patient and public involvement, this proof-of-concept clinical trial will recruit 400 people across four sites in the UK, Spain, the Netherlands, and Germany. Participants must have a recent high blood pressure reading with a clinical need for medication. After providing written consent, they will provide a blood sample (to measure their metabolites) and receive a BP monitor connected to a smartphone app allowing them to measure and record their BP at home throughout the trial.
The study’s main outcome is home BP readings. Participants will also complete web-based questionnaires about their health, diet, treatment experience, and healthcare usage.
Participants will be randomly assigned to two groups. Group A will receive medication based on standard clinical practice up-front, then investigators will receive output from the smart approach to refine the choice of treatment. In Group B, investigators will receive the output from the ‘smart approach’ initially, with further updates provided later.
Only medications licensed for hypertension will be used. All prescriptions are determined by clinicians throughout the trial.
The trial lasts 9-16 weeks. At the end, participants and their usual doctor get a copy of their BP readings and medication to guide their long-term care.
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
25/NW/0296
Date of REC Opinion
4 Nov 2025
REC opinion
Further Information Favourable Opinion